Can Oscar Health's (OSCR) Efficiency Push Offset Rising Medical Costs for Its Long-term Growth Story?

• Oscar Health recently reaffirmed its full-year 2025 growth guidance and outlined cost-saving strategies during presentations at a major healthcare industry conference, despite near-term challenges like elevated medical costs and a recent earnings miss.
• This renewed focus on building the individual market and improving operational efficiency signals Oscar Health’s commitment to long-term profitability by 2026, reinforcing management’s confidence in its position within the evolving healthcare landscape.
• We’ll examine how Oscar Health’s reaffirmed guidance and path to profitability could influence its future growth outlook and investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.

Oscar Health Investment Narrative Recap

To be a shareholder in Oscar Health right now, you need to believe in the company’s ability to grow its individual ACA insurance business and deliver on its forecasted path to profitability, despite current losses and cost pressures. The recent reaffirmation of Oscar’s 2025 growth guidance appears to steady near-term sentiment but does not eliminate the most important short-term catalyst, which remains the normalization of claims costs, nor does it materially reduce Oscar's biggest risk: ongoing pressure from higher market morbidity and regulatory changes.

Among Oscar’s latest announcements, the confirmation of its cost-saving plan, including $60 million in reductions through workforce changes and AI-driven automation, is especially relevant. These efforts are designed to support margin recovery and signal that Oscar is pursuing improved operational efficiency to help counter rising claims and keep to its trajectory for adjusted EBITDA profitability by 2026.

However, despite optimism about digital efficiencies, investors should also be aware that unexpected shifts in claims costs can still...

Read the full narrative on Oscar Health (it's free!)

Oscar Health's outlook anticipates $12.4 billion in revenue and $245.4 million in earnings by 2028. This requires 4.9% annual revenue growth and a $406.6 million increase in earnings from the current -$161.2 million.

Uncover how Oscar Health's forecasts yield a $11.14 fair value, a 43% downside to its current price.

Exploring Other Perspectives

Simply Wall St Community members provided 21 fair value estimates for Oscar Health shares, spanning US$11.14 to US$45.34. As claims cost volatility remains a persistent concern, these diverse viewpoints show how investor opinions on Oscar’s performance potential can differ widely.

Explore 21 other fair value estimates on Oscar Health - why the stock might be worth 43% less than the current price!

Build Your Own Oscar Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Oscar Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Oscar Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oscar Health's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com